Guru P. Sonpavde, MD, presented “Immune Checkpoint Inhibitors: Managing Immune-related Side Effects” at the 6th International Bladder Cancer Update on November 19, 2022, in Scottsdale, Arizona.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Sonpavde, Guru P. “Immune Checkpoint Inhibitors: Managing Immune-related Side Effects.” November 2022. Accessed Nov 2024. https://grandroundsinurology.com/immune-checkpoint-inhibitors-managing-immune-related-side-effects/
Immune Checkpoint Inhibitors: Managing Immune-related Side Effects – Summary
Dr. Guru P. Sonpavde discusses the mechanisms behind immune checkpoint inhibitors and their role in activating the immune system to target and destroy cancer cells. He notes that while these therapies have revolutionized cancer treatment, they also come with the challenge of immune-related side effects. Dr. Sonpavde emphasizes the importance of early detection and management of these adverse effects to ensure patient safety and improve treatment outcomes.
He covers a range of immune-related side effects, including dermatologic, gastrointestinal, hepatic, endocrine, and pulmonary toxicities. Dr. Sonpavde provides detailed insights into the clinical presentation, diagnosis, and treatment of these side effects, drawing from the latest research and clinical guidelines. He stresses the importance of a multidisciplinary approach in managing these toxicities, involving oncologists, dermatologists, endocrinologists, and other specialists to provide comprehensive care for patients.
Dr. Sonpavde highlights strategies for preventing and mitigating immune-related side effects. He discusses the use of corticosteroids and other immunosuppressive agents to manage severe toxicities and the role of patient education in recognizing early symptoms. He also addresses the need for personalized treatment plans that consider the patient’s overall health, comorbidities, and specific risk factors.
About the 6th International Bladder Cancer Update:
The International Bladder Cancer Update (IBCU) is a CME conference focused on the diagnosis and treatment of bladder cancer. The conference offers medical professionals an opportunity to listen to updates from, and interact with, expert international faculty to improve knowledge and determine best treatment practices to improve patient outcomes. IBCU encompasses expert lectures, interactive discussions, a panel roundtable, debates, and case presentations. It is physician-led, multi-supported, and designed for urologists, urologic oncologists, and other healthcare professionals involved in the treatment of bladder cancer.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Guru P. Sonpavde, MD, is the Director of Genitourinary (GU) Oncology and Phase I Research as well as the Christopher K. Glanz Chair for Bladder Cancer Research at the AdventHealth Cancer Institute in Orlando, Florida. Additionally, he holds a position of Professor of Medicine at the University of Central Florida. Previously, Dr. Sonpavde was Bladder Cancer Director at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School from 2017 to 2022. He was also GU Oncology Director and Associate Professor of Medicine at the University of Alabama at Birmingham from 2012 to 2017, and he practiced from 2004 to 2012 at Texas Oncology, a US Oncology affiliate.
Dr. Sonpavde completed his medical oncology and hematology fellowship at Indiana University. His focus is drug development (including early-development Phase I clinical trials and later Phase II/III trials) evaluating immunotherapy, targeted therapy, antibody-drug conjugates, and other novel and emerging classes of treatments (e.g., Bi-Specific T-cell engagers, CAR T-cells) across solid tumors and clinical/translational research to cure GU cancers with a focus on bladder cancer. He serves on the steering committees of several pivotal phase III trials evaluating treatments for bladder cancer. Under his leadership, the Phase I and GU Oncology program have grown robustly at the AdventHealth Cancer Institute. His research efforts have led to around 500 publications.
He also enjoys interacting with medical residents and fellows in order to teach and mentor research projects leading to presentations and publications. He is a member of Southwest Oncology Group, the Scientific Advisory Board of the Bladder Cancer Advocacy Network (BCAN), and the Bladder Cancer Task Force of U.S. NCI GU Steering Committee. He has often contributed to or has been cited in video and written cancer education portals including Uptodate®, Practice Update, Onclive, Physician Education Resource (PER), and Research to Practice. He has also been cited in several lay magazine articles -- most notably in TIME magazine regarding participation in clinical trials in August 2022: https://time.com/6210644/bladder-cancer-clinical-trials/.
Dr. Sonpavde completed his medical oncology and hematology fellowship at Indiana University. His focus is drug development (including early-development Phase I clinical trials and later Phase II/III trials) evaluating immunotherapy, targeted therapy, antibody-drug conjugates, and other novel and emerging classes of treatments (e.g., Bi-Specific T-cell engagers, CAR T-cells) across solid tumors and clinical/translational research to cure GU cancers with a focus on bladder cancer. He serves on the steering committees of several pivotal phase III trials evaluating treatments for bladder cancer. Under his leadership, the Phase I and GU Oncology program have grown robustly at the AdventHealth Cancer Institute. His research efforts have led to around 500 publications.
He also enjoys interacting with medical residents and fellows in order to teach and mentor research projects leading to presentations and publications. He is a member of Southwest Oncology Group, the Scientific Advisory Board of the Bladder Cancer Advocacy Network (BCAN), and the Bladder Cancer Task Force of U.S. NCI GU Steering Committee. He has often contributed to or has been cited in video and written cancer education portals including Uptodate®, Practice Update, Onclive, Physician Education Resource (PER), and Research to Practice. He has also been cited in several lay magazine articles -- most notably in TIME magazine regarding participation in clinical trials in August 2022: https://time.com/6210644/bladder-cancer-clinical-trials/.
